Carisoprodol
Viewing r1 — May 12, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Carisoprodol — Soma — is a synthetic depressant of the propanediol dicarbamate class. It is a structural modification of meprobamate, designed to deliver improved muscle relaxation with reduced abuse liability. Carisoprodol is both a positive allosteric modulator and a direct gating agonist at GABA-A receptors, producing its effects by amplifying inhibitory signaling beyond what GABA alone achieves.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Synthesized by Frank M. Berger and Bernard J. Ludwig at Wallace Laboratories in the early 1950s, carisoprodol was approved for clinical use in 1959 as a purportedly safer successor to meprobamate.[2] That safety promise failed — the compound proved substantially addictive, triggering decades of progressive international scheduling. The European Union withdrew marketing authorization in 2008, the United States placed it in Schedule IV in 2012, and the United Nations added it to Convention Schedule IV in 2025.[3]
Subjective effects include sedation, anxiolysis, muscle relaxation, and psychomotor impairment. The experience is defined by a heavy, body-dominant calm that blankets motor function and cognition simultaneously — more physically engulfing than benzodiazepine sedation, with a characteristic gap between how impaired the user feels and how impaired they actually are.[4] Dizziness, confusion, and delusions of sobriety are common unsought effects.
Carisoprodol produces rapid physical dependence, and the margin between therapeutic and fatal blood concentrations is narrow — death has occurred at levels only modestly above the therapeutic range.[5] Its active metabolite meprobamate accumulates with repeated dosing, compounding both dependence and overdose risk; co-administration with opioids increases overdose risk by 84%.[6] Six decades of clinical use and forensic data provide a substantial evidence base, though key pharmacological questions — including an unexplained serotonergic mechanism — remain unresolved.[7]
History[edit]
Discovery
Carisoprodol was synthesized by pharmacologist Frank M. Berger and chemist Bernard J. Ludwig at Wallace Laboratories, a division of Carter Products, in the early 1950s.[2] The compound was a deliberate modification of meprobamate — Berger's earlier anxiolytic — with a single structural change: addition of an isopropyl group to one carbamate nitrogen. The design objective was a muscle relaxant with reduced abuse potential and greater safety in overdose.
Clinical adoption and emerging abuse
Approved by the FDA in 1959 and marketed as Soma, carisoprodol was widely prescribed for acute musculoskeletal pain through the following decades with limited scrutiny of its abuse liability. That assumption of safety eroded in the 1990s as case reports documented escalating abuse patterns,[8] meprobamate dependence developing from chronic carisoprodol use,[9] and a pattern of dose escalation consistent with tolerance.[10] Norwegian prescription data confirmed the scale of the problem: 15% of patients received doses consistent with tolerance and dependence, strongly associated with concurrent benzodiazepine and opioid use.[11]
Scheduling and market withdrawal
The accumulating evidence triggered a cascade of regulatory actions: Sweden withdrew carisoprodol in 1994, Norway followed in 2008 after rescheduling to its highest level,[12] and the European Union withdrew marketing authorization the same year. The US DEA placed carisoprodol into Schedule IV in January 2012.[13] In 2025, the UN Commission on Narcotic Drugs added it to Schedule IV of the Convention on Psychotropic Substances, obligating all member states to implement domestic controls.[3]
The brand name Soma — shared with the divine intoxicant of Vedic mythology and the pleasure drug of Aldous Huxley's Brave New World — gave carisoprodol a cultural resonance disproportionate to its pharmacological novelty. In street-level drug culture, the name became synonymous with the "Holy Trinity" combination: carisoprodol with an opioid and a benzodiazepine, a polydrug pattern documented across US emergency departments and forensic reports.[14]
Chemistry[edit]
Structural class
Carisoprodol belongs to the propanediol dicarbamate family, sharing its core scaffold with meprobamate. The molecule consists of a 2-methyl-2-propyl-1,3-propanediol backbone bearing two carbamate ester groups — one unsubstituted and one carrying an isopropyl group. This single N-isopropyl substitution is the only structural difference from meprobamate, conferring modestly different pharmacokinetics and receptor selectivity while preserving the same GABA-A targets.[2]
Molecular properties
| Molecular formula | C₁₂H₂₄N₂O₄ |
| Molecular weight | 260.33 g/mol |
The molecule contains no chirality centers — the quaternary carbon at C-2 is achiral due to symmetrical attachment — and no ring systems. Carisoprodol is an open-chain dicarbamate with two carbamate (urethane) ester groups linked through the propanediol spacer.
Physical properties
Carisoprodol is a white crystalline powder, practically insoluble in water but freely soluble in alcohol, chloroform, and acetone.citation needed These lipophilic characteristics facilitate oral absorption. No published data on degradation pathways or long-term storage stability were identified.
Pharmacology[edit]
Mechanism of action
Carisoprodol acts on GABA-A receptors through two distinct mechanisms: it enhances the effect of GABA already present at the receptor (positive allosteric modulation) and directly opens the receptor's chloride channel without GABA being present (direct gating).[1][15] This dual action aligns it pharmacologically with barbiturates rather than benzodiazepines, which can only enhance existing GABA activity.
The direct gating action is strongest at receptors containing α1 subunits and weakest at those containing α3 subunits, a selectivity determined by a single amino acid position in the receptor's transmembrane domain.[16] At certain receptor types found outside synapses, carisoprodol opens the channel more effectively than GABA itself — a pharmacologically unusual property that likely contributes to its pronounced sedation and abuse potential.[1]
Active metabolite
The liver enzyme CYP2C19 converts carisoprodol into meprobamate, which is itself pharmacologically active at GABA-A receptors with barbiturate-like properties.[17] Because meprobamate has a much longer half-life (~10 hours versus ~2 hours for carisoprodol), it accumulates during repeated dosing and contributes substantially to both therapeutic effects and dependence.[17][18]
Serotonergic activity
Case reports document presentations meeting serotonin syndrome criteria — hyperreflexia, involuntary muscle contractions, agitation, and sweating — during carisoprodol intoxication.[7][19] The mechanism is unknown: no receptor binding studies have confirmed whether carisoprodol inhibits serotonin reuptake, stimulates serotonin release, or acts directly on serotonin receptors. This represents a safety-critical pharmacological gap.
The "Holy Trinity"
The combination of carisoprodol with opioids and benzodiazepines produces synergistic effects — both increased dopamine release in reward pathways and compounded respiratory depression.[14] This combination carries substantially increased overdose mortality.
Pharmacokinetics
Carisoprodol reaches peak blood levels approximately 1.5–2 hours after oral administration, with a half-life of roughly 2 hours.[20][18] Its metabolite meprobamate peaks later (3.6–4.5 hours) and persists much longer, with a half-life of approximately 10 hours.
Individuals who are CYP2C19 poor metabolizers experience approximately four-fold higher carisoprodol exposure and roughly half the meprobamate levels of typical metabolizers.[18][21] This genetic variation occurs in 3–5% of Caucasian and African populations and 15–20% of Asian populations — a difference with direct consequences for toxicity risk at standard doses.[21][22]
Food does not significantly affect absorption.[20]
Neuroscience[edit]
Where it acts
Carisoprodol's neural effects center on two populations of GABA-A receptors. At synaptic receptors, it amplifies normal inhibitory signaling, reducing cortical excitability and producing sedation, anxiety relief, and muscle relaxation. At extrasynaptic receptors — found in thalamic relay nuclei, cerebellar granule cells, and the hippocampus — it drives tonic inhibition beyond GABA's own capacity, producing the generalized psychomotor impairment observed even at therapeutic doses.[1][4]
The relative sparing of α3-containing receptors in the brainstem and thalamic reticular nucleus may explain a clinically notable phenomenon: delusions of sobriety, in which users feel substantially less impaired than objective testing reveals.[4]
Reward and dependence
Carisoprodol engages the brain's reward system through GABA-A activation in the ventral tegmental area, releasing dopamine in the nucleus accumbens. When layered with opioid-mediated disinhibition (as in the "Holy Trinity" combination), the resulting dopamine surge is synergistic rather than additive.[14][11]
Chronic use produces GABA-A receptor downregulation, as demonstrated by tolerance and precipitated withdrawal in animal models.[23] The hedonic set point shifts downward with continued exposure, producing a withdrawal state of hyperexcitability — seizures, anxiety, insomnia — that drives compulsive redosing.
Key unknowns include the molecular basis of carisoprodol's serotonergic activity,[7][19] how CYP2C19 metabolizer status modulates subjective experience and abuse liability, and whether the super-agonist activity at extrasynaptic receptors is necessary for the reinforcement.[1] No data exist on whether carisoprodol produces neuroplastic changes.
Subjective Effects[edit]
Carisoprodol delivers a pervasive, body-heavy sedation that envelops motor function, cognition, and mood simultaneously. The effect intensifies along a continuum rather than shifting qualitatively across the dose range — the same sedative-anxiolytic-myorelaxant character deepens with dose, and higher amounts compound impairment without introducing distinct new experiential territory. CYP2C19 metabolizer status and the accumulation of its active metabolite meprobamate during repeated dosing both significantly shape the experience, meaning chronic use feels different from the acute single-dose state.
Compared to benzodiazepines, carisoprodol produces a heavier, more physically dominant sedation with greater psychomotor impairment per unit of subjective high — a consequence of its direct GABA-A channel opening rather than purely allosteric modulation. The closest pharmacological comparator is meprobamate itself, though carisoprodol's faster onset creates a more acute, front-loaded experience before meprobamate's slower contribution extends the tail.
Effect Grid
Pronounced muscle relaxation, moderate sedation, and clear anxiolysis define this range. Thought deceleration becomes evident — cognitive processing slows perceptibly. Delusions of sobriety are characteristic: users feel less impaired than objective testing demonstrates.
Physical effects include noticeable motor control impairment, bodily heaviness, and dizziness. Tactile euphoria may emerge in some individuals. Pain suppression is moderate. Sedation dominates the physical profile without approaching incapacitation.
This encompasses the standard therapeutic range (325-500 mg). Driving and machinery operation are objectively impaired even when the user feels capable. Cognitive euphoria reported by some but not confirmed in controlled settings.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Vestibular distortion · Visual haze / noise · Visual processing suppression
Dizziness · Pain suppression · Bodily heaviness · Body high · Breathing alteration · Nausea · Sexual arousal suppression · Tactile euphoria · Dry mouth · Headache · Nystagmus (eye wobbles) · Vomiting
Breathing alteration · Nausea · Sexual arousal suppression · Tactile euphoria · Dry mouth · Headache · Nystagmus (eye wobbles) · Vomiting
Cognitive fatigue · Focus suppression · Information processing suppression · Language suppression · Pattern recognition suppression · Cognitive euphoria · Confusion · Creativity suppression · Memory suppression · Motivation suppression · Thought disorganization · Compulsive redosing urge · Delusions of sobriety · Memory fragmentation · Amnesia · Delirium
Language suppression · Pattern recognition suppression · Cognitive euphoria · Confusion · Creativity suppression · Memory suppression · Motivation suppression · Thought disorganization · Delusions of sobriety · Memory fragmentation · Amnesia · Delirium
Craving · Sociability suppression
Timeline
Initial awareness of subtle muscle relaxation and mild warmth. Sedation not yet prominent but a softening of baseline tension is perceptible.
Progressive sedation and anxiolysis develop. Motor relaxation deepens noticeably. Thought deceleration begins; a sense of physical heaviness emerges.
Full sedative-anxiolytic-myorelaxant state. Psychomotor impairment maximal. Carisoprodol Cmax reached; meprobamate levels still rising.
Carisoprodol levels declining; meprobamate sustains residual sedation and muscle relaxation. Motor function slowly recovers. Cognitive slowing persists.
Meprobamate-driven residual sedation and physical fatigue. Duration varies substantially by dose and CYP2C19 metabolizer status.
⚠ Do not drive or operate machinery for at least 8 hours after dosing — psychomotor impairment persists beyond subjective awareness of sedation.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- High
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- moderate
- Tolerance reset
- 30 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · barbiturates · alcohol
Toxicity
Acute toxicity
Carisoprodol has a narrow margin between therapeutic and fatal blood concentrations. Levels exceeding 15 mg/L are potentially fatal on their own, and the compound can contribute to death at therapeutic concentrations when combined with other depressants.[5] In cases of solo carisoprodol poisoning, the median blood concentration at death was 36 mg/L.[24]
The fatal toxicity index in Norway (1992–2003) was 5.6–6.9 deaths per million defined daily doses[24] — a rate indicating substantial lethality relative to therapeutic use. Stopped breathing is the primary cause of death.
Carisoprodol has a narrow margin between therapeutic and fatal concentrations, particularly in CYP2C19 poor metabolizers and when combined with other depressants. Respiratory depression is the primary lethal mechanism.
Polydrug overdose
Co-administration with opioids increases overdose risk by 84% (adjusted HR 1.84, 95% CI 1.34–2.54), with risk escalating further when combined treatment exceeds 60 days.[6][25] The "Holy Trinity" combination — carisoprodol with an opioid and a benzodiazepine — carries the highest mortality risk, driven by synergistic respiratory depression.[14]
Fatal outcomes have also been documented with GHB co-ingestion.[26]
Genetic vulnerability
CYP2C19 poor metabolizers face approximately four-fold higher carisoprodol exposure at standard doses.[21] This genetic variation has been directly linked to fatal poisonings at doses considered safe for the general population.[22]
Serotonin syndrome
Case reports document serotonin syndrome presentations — hyperreflexia, involuntary muscle contractions, agitation, sweating — during carisoprodol intoxication.[7][19] The mechanism is unknown. Standard depressant-overdose care may be insufficient; treatment may require specific serotonin-blocking agents and active cooling.safety citation needed
Elderly population
Carisoprodol appears on the American Geriatrics Society Beers Criteria as potentially inappropriate for older adults due to fall risk and CNS adverse effects.citation needed
Psychological risks
Acute psychological effects at higher-than-prescribed doses include elevated mood, confusion, disorientation, and delusions.[3] Delusions of sobriety — a state in which users believe they are far less impaired than they actually are — contribute to driving accidents and other harm.[4]
Abrupt cessation after prolonged high-dose use can produce severe psychiatric symptoms including hallucinations and delirium.[27] Even at the therapeutic dose (350 mg), a measurable gap exists between subjective awareness of impairment and actual psychomotor deficits — patients may perceive themselves as safe to drive while objectively impaired.[4][12]
Tolerance and dependence
Tolerance
Tolerance to carisoprodol develops through GABA-A downregulation, as demonstrated in animal models that also confirmed physical dependence through precipitated withdrawal.[23] The pattern parallels tolerance development seen with barbiturates and benzodiazepines.
Dependence
Physical and psychological dependence are well-documented:
- Meprobamate dependence developing from chronic carisoprodol use[9]
- Escalating abuse patterns with carisoprodol as the primary drug[8][10]
- Severe dependence after 14 years of continuous use[27]
- Documented abuse in North India as an underrecognized phenomenon[28]
- Norwegian data showing 15% of patients received doses consistent with tolerance and dependence, strongly associated with concurrent benzodiazepine and opioid use[11]
Withdrawal
Withdrawal symptoms include anxiety, insomnia, restlessness, craving, and headache. Abrupt cessation after prolonged high-dose use can produce seizures, delusions, and hallucinations.[27] Withdrawal is clinically similar to barbiturate withdrawal and is potentially life-threatening in severe cases. Management typically uses benzodiazepines; severe cases may be resistant to standard treatment.[27]
Cross-tolerance
No published human data exist on cross-tolerance between carisoprodol and other GABA-targeting drugs. By analogy with barbiturates and other direct GABA-A agonists, cross-tolerance with benzodiazepines, alcohol, and barbiturates is expected but unconfirmed. inferred
Drug interactions
CNS depressant synergy
Opioid co-administration increases overdose risk by 84% (adjusted HR 1.84, 95% CI 1.34–2.54), escalating with treatment duration.[6][25] The "Holy Trinity" combination layers carisoprodol's direct GABA-A activation with benzodiazepine enhancement and opioid agonism, producing synergistic respiratory depression.[14] Alcohol and GHB add further respiratory depression; at least one GHB co-ingestion fatality is documented.[26]
Serotonergic interactions
Caution is warranted with all serotonergic agents — SSRIs, SNRIs, MAOIs, tramadol, and triptans — given documented serotonin syndrome cases.[7][19] A fatal case involving sumatriptan and carisoprodol has been reported.[29]
CYP2C19-mediated interactions
CYP2C19 inhibitors (omeprazole, fluoxetine, fluvoxamine) decrease carisoprodol clearance and increase exposure. CYP2C19 inducers (rifampin, carbamazepine, St. John's Wort) accelerate conversion to meprobamate.[20][21]
Fluoxetine is both a CYP2C19 inhibitor (increasing carisoprodol exposure) and a serotonergic agent (compounding serotonin syndrome risk) — a dual-risk combination warranting particular attention.
Contraindications
Absolute
- Known CYP2C19 poor metabolizer status: Standard doses produce approximately four-fold higher exposure, with documented fatal outcomes.[22][21] Alternative muscle relaxants should be used.
- Concurrent opioid therapy: HR 1.84 for overdose;[6] the risk-benefit ratio does not support co-prescription.
- History of meprobamate or carisoprodol hypersensitivity: Cross-reactivity expected given metabolic conversion.[20]
Relative
- Concurrent benzodiazepine or alcohol use: Additive respiratory and CNS depression.[14]
- Treatment duration exceeding 2–3 weeks: Dependence risk increases substantially with prolonged use.[20]
- Elderly patients: Fall risk and CNS adverse effects.citation needed
- Under 16 years: Safety and efficacy not established.[20]
- Pregnancy: No major birth defect risk identified from decades of use, but formal safety studies are lacking.[20]
- Concurrent serotonergic agents: Serotonin syndrome documented.[7][19]
- CYP2C19 inhibitor co-administration: Mimics poor metabolizer phenotype.[21]
Harm Reduction[edit]
Forms & Identification
Carisoprodol is prescribed as oral tablets, typically 250 mg or 350 mg. Because it is a pharmaceutical product, identification centers on verifying that the tablet matches its claimed source — diverted prescription tablets may be genuine, but street-level formulations have appeared combining carisoprodol with other active ingredients (notably "red apple" tablets containing tapentadol, identified in UK harm reduction monitoring[3]). Standard urine drug screens do not detect carisoprodol specifically; confirmation requires specialized laboratory methods.
Pill identification resources can verify imprint codes against manufacturer databases, but cannot confirm the absence of adulterants. Any tablet obtained outside a verified pharmacy supply chain should be treated as potentially adulterated.
Guidelines
- Verify that tablets come from a licensed pharmacy with matching prescription. Treat any tablet from an unverified source as potentially containing other active substances.
- Do not exceed the prescribed dose. The margin between therapeutic and dangerous blood concentrations is narrow.[5]
- Do not combine with opioids, benzodiazepines, alcohol, or GHB. Each combination increases overdose risk substantially.[6][14]
- Do not drive or operate machinery. Impairment is present even when the user feels sober.[4]
- Limit use to the shortest possible duration. Dependence can develop within weeks.[20]
- Do not stop abruptly after prolonged use. Withdrawal from carisoprodol can produce seizures and is potentially life-threatening.[27] Taper under medical supervision.
- If you are of East Asian descent, be aware that CYP2C19 poor metabolizer status (15–20% prevalence) produces approximately four-fold higher drug exposure at standard doses.[21]
Set & Setting
Carisoprodol's most dangerous characteristic is delusions of sobriety — the gap between perceived and actual impairment is measurable even at the standard therapeutic dose.[4] This makes self-assessment of fitness to drive, operate machinery, or make decisions unreliable.
A sedentary, safe environment is essential. Driving, climbing stairs, cooking, or any activity requiring coordination should be avoided for the full duration of effects. If using at home, inform someone present that impairment may not be visible to the user.
Aftercare & integration. Carisoprodol's sedative effects resolve within hours, but meprobamate's longer half-life (~10 hours) means residual impairment may persist into the following day — particularly after repeated dosing. Plan for reduced coordination and slowed reaction times the morning after use.
If using as prescribed for musculoskeletal pain, monitor whether the same dose continues to provide relief. Diminishing effectiveness within the first two weeks is an early signal of tolerance development and should prompt a conversation with the prescribing clinician rather than dose escalation.
Recovery & Support
Carisoprodol dependence shares characteristics with barbiturate and benzodiazepine dependence. Withdrawal is potentially life-threatening and must not be attempted without medical supervision.[27] A supervised taper, typically using benzodiazepines, is the standard approach.
Because carisoprodol abuse frequently co-occurs with opioid and benzodiazepine use,[11] recovery planning should address all concurrent substance use. Support resources include SAMHSA's National Helpline (1-800-662-4357), local addiction medicine services, and mutual aid groups familiar with sedative-hypnotic dependence.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Slow, shallow, or stopped breathing
- Blue or grey lips or fingertips
- Unresponsiveness or inability to be roused
- Seizures
- Hyperreflexia, muscle rigidity, or involuntary jerking (may indicate serotonin syndrome[7])
Immediate steps:
- Call emergency services immediately if breathing is slow, irregular, or absent.
- Place the person in the recovery position (on their side) to prevent choking.
- Monitor breathing continuously until help arrives.
- Do not induce vomiting.
- Do not leave the person alone.
What to tell the dispatcher:
- The substance taken (carisoprodol / Soma), the amount if known, and the time of ingestion.
- Any other substances taken — especially opioids, benzodiazepines, or alcohol.
- Current symptoms: breathing rate, responsiveness, any seizure activity or muscle rigidity.
- Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Carisoprodol's legal status has undergone progressive tightening over six decades, driven by accumulating evidence of abuse, dependence, and fatal overdose. Unscheduled at its 1959 introduction, the compound remained uncontrolled at the US federal level until 2012. The 2025 placement under Schedule IV of the UN Convention on Psychotropic Substances (CND Decision 68/6) now obligates all member states to implement domestic controls.[3]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule IV (Controlled Substances Act) | DEA final rule published 12 December 2011; effective 11 January 2012[13] |
| European Union | Marketing authorization withdrawn | Withdrawn 2008; no longer available through standard prescription[12] |
| Norway | Highest scheduling; market withdrawal | Rescheduled 1 August 2007; market withdrawal 1 May 2008. Post-withdrawal surveillance confirmed reduced harms[12] |
| United Kingdom | Not currently controlled under MDA 1971; ACMD recommending Class C, Schedule 4 | ACMD report 2025; UN Convention obligation pending domestic implementation[3] |
| Canada | Schedule V controlled substance | Removed from Prescription Drug List; reclassified as of 14 April 2025citation needed |
| Australia | Not on Australian Register of Therapeutic Goods | Accessible via Special Access Scheme onlycitation needed |
| South Korea | Controlled substance | Controls implemented following documented abuse and fatalities[30] |
| Sweden | Market withdrawal | Withdrawn 1994citation needed |
| India | Available in some states; no national scheduling | Documented abuse, particularly in North India[28] |
| International | UN Convention on Psychotropic Substances, Schedule IV | CND Decision 68/6, 2025[3] |
Street-level availability in the UK has been documented through "red apple" formulations combining carisoprodol with tapentadol, identified through harm reduction monitoring.[3] Standard urine immunoassays do not typically screen for carisoprodol; confirmation requires GC-MS or equivalent analytical methods.
references
- [1]
- [2] ^abcBerger F, Kletzkin M, Ludwig B, Margolin S (1960) THE HISTORY, CHEMISTRY, AND PHARMACOLOGY OF CARISOPRODOL — Annals of the New York Academy of Sciences doi:10.1111/j.1749-6632.1960.tb42792.x
- [3]
- [4]
- [5] ^abcMcIntyre IM, Sherrard J, Lucas J (2012) Postmortem carisoprodol and meprobamate concentrations in blood and liver: lack of significant redistribution — Journal of Analytical Toxicology doi:10.1093/jat/bks011
- [6]